CV Sciences (CVSI) AI Stock Analysis

• Market Cap: $4.98M
• Dividend Yield: N/A
• Average Volume (3M): 273.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.13
• Revenue Growth: -3.46%
• EPS Growth: 49.51%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 58
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 184,263,660
• 10 Day Avg. Volume: 167,376
• 30 Day Avg. Volume: 273,373
• PEG Ratio: <0.01
• Price to Book (P/B): -5.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.37
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 0.09
• Enterprise Value/Gross Profit: 0.77
• Enterprise Value/Ebitda: -0.71
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: $0.00 ▼(-100.00%Downside)

The most significant factor affecting CV Sciences' stock score is its poor financial performance, characterized by declining revenues and negative profit margins. Technical analysis indicates some short-term bullish signals, but overall weakness persists. Valuation metrics are very poor, with a negative P/E ratio. The earnings call offered some optimism with improved cost efficiencies and strategic initiatives, but these are overshadowed by ongoing challenges.

CV Sciences Business Overview & Revenue Model

Company Description

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

How the Company Makes Money

CV Sciences generates revenue through the sale of its CBD-based products, mainly under the PlusCBD™ brand. The company sells these products through various distribution channels, including direct-to-consumer sales via their website, retail partnerships, wholesalers, and other e-commerce platforms. Key revenue streams include a range of CBD formulations such as oils, capsules, gummies, and topicals, which cater to diverse consumer needs for wellness and health. The company may also engage in strategic partnerships and collaborations that enhance its market presence and distribution capabilities, contributing to its earnings.

CV Sciences Financial Statement Overview

Summary

CV Sciences faces significant financial challenges, including declining revenues, negative profit margins, and cash flow issues. The high debt-to-equity ratio and low equity ratio further highlight potential financial stability risks.

Income Statement

The company has faced a declining revenue trend over the years, with a notable drop from 2019 to 2024. Gross profit margins have decreased significantly, indicating cost pressure. The EBIT and net profit margins are negative, reflecting operational inefficiencies and consistent net losses.

Balance Sheet

The company exhibits a high debt-to-equity ratio, indicating potential leverage risks. The equity ratio is low, highlighting limited funding from shareholders relative to total assets. However, there has been a reduction in total liabilities over time, which is a positive sign.

Cash Flow

Cash flow from operations has been consistently negative, pointing to cash generation challenges. Free cash flow is also negative, indicating a lack of surplus cash after capital expenditures. The operating cash flow to net income ratio suggests operational struggles.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
15.31M	15.71M	16.00M	16.20M	20.05M	24.43M
	Gross Profit
6.97M	7.17M	7.08M	5.55M	8.62M	11.01M
	EBIT
-1.56M	-2.19M	3.36M	-6.85M	-18.45M	-22.59M
	EBITDA
-1.27M	-1.86M	3.85M	-5.66M	-14.00M	-21.72M
	Net Income Common Stockholders
-1.88M	-2.39M	3.10M	-8.21M	-15.55M	-22.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
812.00K	454.00K	1.32M	611.00K	1.38M	4.02M
	Total Assets
7.76M	7.93M	9.20M	12.74M	18.07M	30.63M
	Total Debt
1.02M	779.00K	442.00K	1.53M	922.00K	7.77M
	Net Debt
213.00K	325.00K	-875.00K	917.00K	-453.00K	3.75M
	Total Liabilities
5.87M	6.13M	6.30M	13.51M	14.52M	19.41M
	Stockholders Equity
1.89M	1.79M	2.90M	-777.00K	3.54M	11.21M
Cash Flow		Free Cash Flow
-482.00K	-879.00K	2.25M	-1.89M	-7.52M	-8.36M
	Operating Cash Flow
-424.00K	-861.00K	2.25M	-1.89M	-7.49M	-7.30M
	Investing Cash Flow
-68.00K	-28.00K	-156.00K	0.00	-35.00K	-1.06M
	Financing Cash Flow
648.00K	32.00K	-1.39M	1.12M	4.37M	3.27M

CV Sciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Neutral. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.51 is Neutral, neither overbought nor oversold. The STOCH value of 136.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVSI.

CV Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	60 Neutral	$12.03M	―	3.29%	―	-26.17%	―
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
FLGC	46 Neutral	$17.58M	―	-336.65%	―	-28.78%	86.97%
CVSI	41 Neutral	$4.98M	―	-88.15%	―	-3.46%	49.51%
YCBD	30 Underperform	$7.69M	―	-8.46%	―	-9.22%	89.90%
PTPI		$1.05M	―	-2407.84%	―	―	―
AKAN		$3.06M	―	-1460.27%	―	―	―

CV Sciences Corporate Events

CV Sciences Holds 2025 Virtual Annual Meeting

On June 2, 2025, CV Sciences, Inc. held its 2025 Annual Meeting virtually, with approximately 54.6% of the outstanding shares represented by proxy. During the meeting, stockholders elected three directors, ratified the selection of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approved the executive officer compensation on a non-binding advisory basis, and decided that the advisory vote on executive compensation should occur every two years.

CV Sciences Reports Q1 2025 Financial Results

On May 14, 2025, CV Sciences announced its financial results for the first quarter of 2025, reporting a revenue of $3.6 million, a decrease from the previous year due to lower sales volume. Despite this, the company achieved an operating income of $11,000, an improvement from a loss in the previous year, attributed to reduced operating expenses and a reversal of accrued payroll taxes. The company also launched a new plant-based product line, Lunar Fox, targeting the growing vegan food market, marking a significant step in its transition to a global health and wellness company.

CV Sciences Reports 2024 Financial Results and Growth Plans

CV Sciences reported its financial results for the fiscal year ending December 31, 2024, with revenues of $15.7 million, a slight decline from the previous year. The company achieved a gross margin improvement to 45.6% and reduced operating expenses by 5.4%. Despite an operating loss of $2.2 million, the adjusted EBITDA loss improved significantly. The company expanded its product offerings with new launches and strategic partnerships, including the acquisition of Elevated Softgels and the launch of the Lunar Fox plant-based product line. CV Sciences aims to continue its growth trajectory through innovation and strategic mergers and acquisitions.